Cargando…
Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926957/ https://www.ncbi.nlm.nih.gov/pubmed/36683350 http://dx.doi.org/10.1002/cac2.12400 |
| _version_ | 1784888381664133120 |
|---|---|
| author | Zou, Limin Qi, Yueli Jiang, Yongling Tang, Ling Du, Yu Zhao, Boyuan Sun, Yanzhe Xiang, Meiyi Ma, Jun Yang, Zhimin |
| author_facet | Zou, Limin Qi, Yueli Jiang, Yongling Tang, Ling Du, Yu Zhao, Boyuan Sun, Yanzhe Xiang, Meiyi Ma, Jun Yang, Zhimin |
| author_sort | Zou, Limin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9926957 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99269572023-02-16 Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers Zou, Limin Qi, Yueli Jiang, Yongling Tang, Ling Du, Yu Zhao, Boyuan Sun, Yanzhe Xiang, Meiyi Ma, Jun Yang, Zhimin Cancer Commun (Lond) Editorial John Wiley and Sons Inc. 2023-01-22 /pmc/articles/PMC9926957/ /pubmed/36683350 http://dx.doi.org/10.1002/cac2.12400 Text en © 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Editorial Zou, Limin Qi, Yueli Jiang, Yongling Tang, Ling Du, Yu Zhao, Boyuan Sun, Yanzhe Xiang, Meiyi Ma, Jun Yang, Zhimin Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers |
| title | Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers |
| title_full | Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers |
| title_fullStr | Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers |
| title_full_unstemmed | Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers |
| title_short | Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers |
| title_sort | criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in china: from the perspective of clinical reviewers |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926957/ https://www.ncbi.nlm.nih.gov/pubmed/36683350 http://dx.doi.org/10.1002/cac2.12400 |
| work_keys_str_mv | AT zoulimin criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT qiyueli criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT jiangyongling criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT tangling criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT duyu criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT zhaoboyuan criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT sunyanzhe criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT xiangmeiyi criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT majun criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers AT yangzhimin criteriaandregulatoryconsiderationsfortheconditionalapprovalofinnovativeantitumordrugsinchinafromtheperspectiveofclinicalreviewers |